Samertan is chemically described as 4'--1'-yl)methyl]--2-carboxylic acid. Its empirical formula is C33H30N4O2, its molecularweight is 514.63, and itsstructuralformulais:
Samertan is a white to slightly yellowish solid. It is practically insoluble in water and in the pH range of 3 to 9, sparingly soluble in strong acid (except insoluble in hydrochloric acid), and soluble in strong base.
MICARDIS is available as tablets for oral administration, containing 20 mg, 40 mg or 80 mg of Samertan. The tablets contain the following inactive ingredients: sodium hydroxide, meglumine, povidone, sorbitol, and magnesium stearate. MICARDIS tablets are hygroscopic and require protection from moisture.
COMMON BRAND(S): Micardis
GENERIC NAME(S): Samertan
OTHER NAME(S): Samertan Tablet
This drug can cause serious (possibly fatal) harm to an unborn baby if used during pregnancy. Therefore, it is important to prevent pregnancy while taking this medication. Consult your doctor for more details and to discuss the use of reliable forms of birth control while taking this medication. If you are planning pregnancy, become pregnant, or think you may be pregnant, tell your doctor right away.
This medication is used to treat high blood pressure (hypertension). Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. Samertan belongs to a class of drugs called angiotensin receptor blockers (ARBs). It works by relaxing blood vessels so blood can flow more easily.
Plasma concentrations of Samertan are generally 2 to 3 times higher in females than in males. In clinical trials, however, no significant increases in blood pressure response or in the incidence of orthostatic hypotension were found in women. No dosage adjustment is necessary.
What are the uses for Samertan?
Samertan is used for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.
Samertan is used for reducing the risk of heart attack, stroke, or death from cardiovascular causes in patients 55 years of age or older who are at high risk for developing major cardiovascular events and unable to take ACE inhibitors. High risk for cardiovascular events can be evidenced by a history of coronary artery disease, peripheral arterial disease, stroke, transient ischemic attack, or high-risk diabetes (insulin-dependent or non-insulin dependent) with evidence of end-organ damage.
Abbreviations: ARB, angiotensin receptor blocker; CI, confidence interval; DDD, defined daily dose; HR, hazard ratio.
*P for trend >0.05 for both analyses.
Table 3 presents the results stratified according to cancer type. Overall, compared with other ARBs, the use of Samertan was not associated with a statistically significant increased risk of lung, breast, prostate, or colorectal cancer. Adjusted HRs ranged between 0.79 and 1.41 with all CIs spanning the null value. In contrast, Samertan was associated with 17% decreased risk of other cancers (adjusted HR: 0.83, 95% CI: 0.70–0.99). In secondary analyses ( Supplementary Data – Supplementary Data ), a cumulative duration of less than 2 years and a cumulative dose less than 730 DDDs were both associated with an increased risk of colorectal cancer ( Supplementary Data ), but there was no clear duration- and dose-response relationship. Varying the latency time window from 1 to 2 years d >Supplementary Data ).
Crude and adjusted HRs of lung, breast, prostate, and colorectal cancers associated with Samertan use compared with other ARBs
What is Samertan (Micardis)?
Samertan is used to treat high blood pressure (hypertension), sometimes in combination with other blood pressure medications.
Samertan is also used to reduce the risk of stroke, heart attack, or death from heart problems in people who are at least 55 years old with risk factors for serious heart disorders.
Samertan may also be used for purposes not listed in this medication guide.
Occasional elevations of liver chemistries occurred in patients treated with Samertan; all marked elevations occurred at a higher frequency with placebo. No Samertan-treated patients discontinued therapy because of abnormal hepatic function.
Do not use if you are pregnant, and tell your doctor right away if you become pregnant.
If you have diabetes, do not use Samertan together with any medication that contains aliskiren (a blood pressure medicine).
What should I avoid while taking Samertan (Micardis)?
Avoid getting up too fast from a sitting or lying position, or you may feel dizzy.
Do not use potassium supplements or salt substitutes, unless your doctor has told you to.
How should I take Samertan?
Follow all directions on your prescription label and read all medication guides or instruction sheets. Your doctor may occasionally change your dose. Use the medicine exactly as directed.
You may take Samertan with or without food.
Swallow the tablet whole and do not crush, chew, or break it.
Keep each tablet in its blister pack until you are ready to take it. Tear or cut the blister apart from the rest of the package and peel back the paper liner. Push the tablet through the foil to remove it.
Your blood pressure will need to be checked often.
You may have very low blood pressure while taking Samertan. Call your doctor if you are sick with vomiting or diarrhea, or if you are sweating more than usual.
It may take 2 to 4 weeks before you receive the full benefit of taking Samertan. Your doctor will determine how long to treat you with this medicine.
If you have high blood pressure, keep using this medicine even if you feel well. High blood pressure often has no symptoms. You may need to use blood pressure medicine for the rest of your life.
Store Samertan tablets in their original package at room temperature, away from moisture and heat.
Storage And Handling
MICARDIS is available as white or off-white, uncoated tablets containing Samertan 20 mg, 40 mg, or 80 mg. Tablets are marked with the Boehringer Ingelheim company symbol on one side, and on the other side, with either 50H, 51H, or 52H for the 20 mg, 40 mg, and 80 mg strengths, respectively. Tablets are provided as follows:
MICARDIS tablets 20 mg are round and individually blister-sealed in cartons of 30 tablets as 3 x 10 cards (NDC 0597-0039-37).
MICARDIS tablets 40 mg are oblong shaped and individually blister-sealed in cartons of 30 tablets as 3 x 10 cards (NDC 0597-0040-37).
MICARDIS tablets 80 mg are oblong shaped and individually blister-sealed in cartons of 30 tablets as 3 x 10 cards (NDC 0597-0041-37).
Samertan oral tablet is a prescription drug that’s available as the brand-name drug Micardis. It’s also available as a generic drug. Generic drugs usually cost less than the brand-name version. In some cases, they may not be available in all strengths or forms as the brand-name drug.
A 0.5 mg/dL rise or greater in creatinine was observed in 0.4% Samertan patients compared with 0.3% placebo patients. One Samertan-treated patient discontinued therapy because of increases in creatinine and blood urea nitrogen.